He holds 12 US patents related to his research. Some formulations that he invented or co-invented are currently used in the clinic. Among these, Abelcet® is being marketed for treatment of fungal infections and Atragen® (for inducing long-term remissions in APL patients) and Lipo-Cur® (for treating pancreatic cancer) are undergoing clinical trials. He serves on Editorial Boards of several journals and has chaired or co-chaired many scientific meetings, including the Gordon Research Conference and FASEB Summer Conference. He has published more than 180 scientific articles and edited four books, including the most recent one on 'Drug resistance in Cancer Cells'.